Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cabaletta Bio, Inc.CABA · Entity 5418 | Chief Commercial Officer | January 21, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cabaletta Bio, Inc.
Report date January 21, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,170 |
Reported balance
After 2026-01-21 transaction · row 1
1 source rowRow 1 · 2026-01-21 · Purchase · Acquired 22,170 · Balance 22,170 F1: The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $2.26 to $2.27, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $2.26 to $2.27, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 21, 2026 18:55 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | PurchaseCommon Stock | 22,170 | $2.27 | $50,215.05 |
DisclosureSEC source: 0001193125-26-018323 · ownership.xml · nonDerivative · entry 1 Gavel Steve · CIK 0002090785 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,170 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $2.26 to $2.27, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 16:39 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001193125-25-240356 · ownership.xml · derivative · entry 1 Gavel Steve · CIK 0002090785 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-10-12 F1 · shares: The stock option has been granted pursuant to the Cabaletta Bio, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4). F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 13, 2026, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.